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Background.  —  The  frequencies  of  treatment  for  cardiovascular  risk  factors  are  poorly  docu-
mented in  large  populations,  particularly  according  to  the  presence  or  absence  of  cardiovascular
disease (CVD).
Aims.  —  To  assess  frequencies  of  reimbursements  for  antihypertensive,  lipid-lowering  and
antidiabetic  medications  in  France  among  national  health  insurance  beneﬁciaries  in  2010  and
their associations  according  to  age,  sex,  French  regions,  level  deprivation  and  the  presence  of
certain CVD.
Methods.  —  Treatment  frequencies  were  calculated  among  the  beneﬁciaries  (58  million  people)
on the  basis  of  reimbursements  for  three  speciﬁc  categories  of  medicinal  products  in  2010.  The
presence of  CVD  was  deﬁned  by  a  diagnosis  associated  with  chronic  disease  status  and  hospital
stays in  2010.
Abbreviations: ALD, Affections de Longue Durée; ATC, Anatomical Therapeutic Chemical Classiﬁcation System; CVD, Cardiovascular
isease; ENNS, Étude Nationale Nutrition Santé; PMSI, Programme de Médicalisation des Systèmes d’Information; SNIIRAM, Système National
’Information Inter-régimes de l’Assurance Maladie.
∗ Corresponding author. Fax: +33 1 72 60 17 26.
E-mail address: philippe.tuppin@cnamts.fr (P. Tuppin).
875-2136/$ — see front matter © 2013 Elsevier Masson SAS. All rights reserved.
ttp://dx.doi.org/10.1016/j.acvd.2013.02.005
Frequency  of  treatment  of  cardiovascular  risk  factors  in  France  275
Results.  —  Among  people  aged  greater  or  equal  to  20  years,  treatment  frequencies  were  22%
(men 20%  vs.  women  23%)  for  antihypertensives,  15%  (14%  vs.  16%)  for  lipid-lowering  agents  and
6% (6%  vs.  5%)  for  antidiabetic  medications.  These  frequencies  were,  respectively,  33%,  23%  and
8% in  patients  aged  greater  or  equal  to  40  years  and  55%,  38%  and  14%  in  patients  aged  greater
or equal  to  60  years.  The  frequency  of  at  least  one  treatment  for  at  least  one  of  the  three  risk
factors was  41%  in  patients  aged  greater  or  equal  to  40  years  and  66%  in  patients  aged  greater
or equal  to  60  years.  Among  patients  aged  greater  or  equal  to  20  years,  22%  were  treated
for at  least  one  risk  factor  in  the  absence  of  CVD  and  3%  were  treated  for  at  least  one  risk
factor in  the  presence  of  CVD.  Regional  differences  were  observed,  with  higher  frequencies  of
antihypertensive  and  antidiabetic  use  in  the  North,  North-East  and  Overseas  regions.  Treatment
frequencies  increased  with  level  of  deprivation,  especially  for  antidiabetics.
Conclusion.  —  This  national  study  more  clearly  deﬁnes  treatment  frequencies  and  the  popula-
tions and  regions  with  the  highest  treatment  frequencies.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Contexte.  —  Les  fréquences  de  traitements  des  facteurs  de  risque  cardiovasculaire  sont  peu
connues dans  de  larges  populations,  particulièrement  selon  la  présence  ou  non  d’une  maladie
cardiovasculaire  (MCV).
Objectifs.  —  Décrire  les  fréquences  nationales  et  régionales  des  traitements  anti-
hypertenseurs,  antidiabétiques  et  hypolipémiants  et  de  leurs  associations  en  France  parmi  les
assurés du  régime  général  de  l’assurance  maladie  selon  l’âge,  le  sexe,  la  région,  le  niveau  de
défavorisation  et  la  présence  de  certaines  MCV.
Méthodes.  —  Ces  fréquences  ont  été  calculées  parmi  ces  assurés  (58  millions),  sur  la  base  de
trois remboursements  de  médicaments  spéciﬁques  en  2010.  L’existence  d’une  MCV  a  été  déﬁnie
par les  diagnostics  des  affections  de  longue  durée  et  des  séjours  hospitaliers  en  2010.
Résultats. —  Chez  les  personnes  de  20  ans  et  plus,  la  fréquence  d’un  traitement  anti-
hypertenseur  était  de  22  %  (hommes  20  %,  femmes  23  %),  d’un  hypolipémiant  de  15  %  (14  %  vs
16 %)  et  d’un  antidiabétique  de  6  %  (6  %  vs  5  %).  Après  40  ans,  elles  étaient  de  33  %,  23  %  et  8  %  et
après 60  ans  de  55  %,  38  %  et  14  %.  La  fréquence  d’au  moins  un  traitement  pour  au  moins  un  des
trois facteurs  était  de  41  %  pour  ceux  de  40  ans  et  plus  et  de  66  %  pour  ceux  de  60  ans  et  plus.
Parmi les  personnes  de  20  ans  et  plus,  22  %  avaient  au  moins  un  facteur  de  risque  traité  et  pas  de
MCV, et  3  %  au  moins  un  facteur  traité  et  une  MCV.  Des  fréquences  plus  élevées  de  l’utilisation
d’anti-hypertenseurs  et  d’antidiabétiques  étaient  constatées  dans  les  régions  Nord,  Nord-Est
et Outremer.  Les  fréquences  des  traitements  augmentaient  avec  le  niveau  de  défavorisation,
surtout  pour  les  antidiabétiques.
Conclusions.  — Cette  étude  nationale  permet  de  mieux  connaître  les  fréquences  des  traitements
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Background
Cardiovascular  diseases  (CVD)  are  a  leading  cause  of  health-
care  consumption,  disability  and  mortality  in  industrialized
countries.  Although  the  number  of  people  affected  by  CVD  is
increasing,  standardized  morbidity  and  mortality  are  declin-
ing  as  a  result,  among  other  factors,  of  improved  early
management  of  recognized  diseases  by  aggressive  treat-
ment,  but  also  improved  treatment  of  cardiovascular  risk
factors  [1—8].
Compared  with  other  European  countries,  in  2008,  France
had  the  lowest  standardized  mortality  rate  for  ischaemic
heart  disease  and  the  second  lowest  standardized  mortality
rate  for  stroke  among  patients  aged  45—74  years,  for  both
men  and  women  [9].  These  data  are  conﬁrmed  by  morbidity
data,  as  the  three  French  MONICA  registries  reported  a  sig-
niﬁcant  mean  19%  decrease  in  rates  of  myocardial  infarction
and  coronary  mortality  between  2000—2003  and  2004—2007
c
l
cs  droits  réservés.
or  both  sexes,  and  the  Dijon  registry  reported  a  stable
ncidence  of  stroke  between  1985  and  2004  with  a  more
dvanced  age  of  onset  [10,11]. The  standardized  national
ospitalization  rate  for  myocardial  infarction  decreased  by
7%  between  2002  and  2008.  This  reduction  was  more
arked  among  those  aged  greater  or  equal  to  65  years
—22%).  Before  the  age  of  65  years,  hospitalization  rate
ecreased  for  men  (—10%),  but  increased  for  women  (+7%)
12]. The  annual  hospitalization  rate  for  stroke  decreased  by
%  overall,  but  increased  by  11%  before  the  age  of  65  years
13]. Surveillance  of  the  levels  of  primary  prevention  of  CVD
nd  their  impact  in  these  populations  therefore  remains  a
riority,  including  in  the  youngest.
The  prevalence  rates,  treatment  and  control  of  car-
iovascular  risk  factors  are  usually  measured  by  repeated
ross-sectional  studies  in  samples  from  the  general  popu-
ation,  generally  based  on  self-reported  medication

















































































































xamination  and  laboratory  tests  [14,15].  However,  sub-
roup  analyses  are  usually  difﬁcult  due  to  the  small  sample
izes.  Hypertension,  diabetes  and  hyperlipidaemia  are
ardiovascular  risk  factors  accessible  to  drug  treatments,
he  use  of  which  has  been  poorly  studied  in  national
dministrative  databases.
The  present  study  was  designed  to  assess  national  and
egional  frequencies  of  reimbursements  for  antihyperten-
ive,  lipid-lowering  and  antidiabetic  medications  in  France
mong  national  health  insurance  beneﬁciaries  in  2010  and
heir  associations  according  to  age,  sex,  French  regions,
evel  deprivation  and  the  presence  of  certain  CVD.
ethods
n  2010,  the  Régime  Général  de  l’Assurance  Maladie  (French
ational  health  insurance  general  scheme)  covered  about
8  million  people  living  in  France,  i.e.  almost  90%  of
he  French  population  and  almost  75%  of  the  population
fter  the  exclusion  of  local  mutualist  sections.  The  Sys-
ème  National  d’Information  Inter-Régimes  de  l’Assurance
aladie  (SNIIRAM;  French  national  interscheme  health  insur-
nce  information  system)  comprises  an  individual  and
nonymous  database,  which  comprehensively  records  all
ealthcare  consumption,  ambulatory  care  or  outpatient
isits,  reimbursed  by  national  health  insurance,  with  histor-
cal  data  limited  to  a  period  of  3  years  plus  the  current  year
16].  Other  information  is  also  available,  such  as  the  town  of
esidence,  100%  reimbursement  of  care  for  certain  chronic
iseases  (Affections  de  Longue  Durée  [ALD]),  based  on  the
pinion  of  the  national  health  insurance  general  scheme
onsultant  physician.  All  this  information  can  be  linked  to
ata  collected  in  healthcare  institutions  by  the  Programme
e  Médicalisation  des  Systèmes  d’Information  (PMSI;  med-
calized  information  systems  programme)  using  the  unique
nonymous  patient  identiﬁer  generated  from  the  Numéro
’Inscription  au  Répertoire  des  personnes  physiques  (social
ecurity  number).  Diagnoses  are  coded  in  PMSI  according
o  the  International  Classiﬁcation  of  Diseases,  10th  edition
ICD-10),  which  is  also  used  to  code  diseases  corresponding
o  ALD.
The  study  population  comprised  national  health  insur-
nce  general  scheme  beneﬁciaries  for  whom  at  least  one
ealthcare  reimbursement  in  2010  was  recorded  in  SNIIRAM.
his  criterion  was  justiﬁed  by  the  fact  that  survival  and  date
f  death  are  only  available  for  general  scheme  beneﬁciaries
about  75%  of  the  population)  and  not  for  the  beneﬁciaries
f  other  schemes  managed  by  local  mutualist  sections  in  SNI-
RAM.  As  the  survival  status  was  not  available  for  all  patients,
he  selection  of  beneﬁciaries  in  whom  at  least  one  health-
are  reimbursement  in  2010  was  recorded  therefore  ensures
hat  all  beneﬁciaries  of  the  general  scheme,  including  local
utualist  sections,  were  alive  in  2010.  Some  beneﬁciaries
ould  not  be  included  due  to  the  absence  of  reimbursement
n  the  SNIIRAM  database,  because  their  treatments  were
nanced  directly  by  the  institution  (for  example  medical
nd  social  welfare  institutions)  and  were  therefore  not  reim-
ursed  individually,  or  because  they  had  no  reimbursement
hatsoever  during  the  index  year.
The  presence  of  CVD  was  estimated  by  the  presence  of
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010  and/or  the  presence  of  a  short-stay  hospitalization  in
010  with  CVD  ICD-10  codes  in  any  position  (main,  asso-
iated  or  related  diagnosis).  Selected  CVD  were  coronary
eart  disease  and  myocardial  infarction  (I20  to  I25),  stroke
I61  to  I66,  I69,  G45)  and  peripheral  artery  disease  (I70.2),
rouped  under  the  term  CVD.  National  health  insurance  ben-
ﬁciaries  with  other  CVD  codes  not  included  above  were
xcluded  to  eliminate  people  with  CVD  not  known  to  be
ighly  associated  with  the  cardiovascular  risk  factors  stud-
ed.
The  presence  of  a  treatment  for  one  of  the  deﬁned
isk  factors  was  estimated  by  the  presence  of  three  or
ore  reimbursements  recorded  in  the  database  in  2010
or  two  prescriptions  in  the  case  of  large  packaging)
or  at  least  one  indicated  medicinal  product.  Medicinal
roducts  were  identiﬁed  in  the  SNIIRAM  by  ATC  class
Anatomical  Therapeutic  Chemical  Classiﬁcation  System)
nd  the  corresponding  Code  Identiﬁant  de  Présentation
CIP;  presentation  identiﬁcation  code).  Medicinal  prod-
cts  indicated  for  diabetes  corresponded  to  ATC  class  A10
drugs  used  in  diabetes).  Indicated  antihypertensive  med-
cations  were  those  for  which  the  Marketing  Authorization
peciﬁed  an  indication  in  the  treatment  of  hyperten-
ion  (i.e.  class  C02,  antihypertensive;  C03,  diuretics;  C07,
eta  blocking  agents;  C08,  calcium  channel  blockers;
nd  C09,  agents  acting  on  the  renin-angiotensin  system).
lass  C10  was  used  to  identify  treatments  for  hyperlipi-
aemia.
For  each  of  the  three  risk  factors  considered,  treatment
requencies  of  one  or  several  risk  factors  and  their  associa-
ions  by  age,  sex  and  region  and  according  to  the  presence
r  absence  of  CVD  were  calculated  on  the  basis  of  the
opulations  of  beneﬁciaries  with  any  healthcare  consump-
ion  reported  during  2010.  Some  age  groups  were  combined
≥  20  years;  ≥  40  years;  ≥  60  years;  18—74  years)  to  allow
ational  or  international  comparisons.  Regional  frequencies
ere  standardized  according  to  sex  and  age  of  the  popula-
ion  of  the  general  scheme  beneﬁciaries  of  the  Répertoire
ational  Inter-régimes  des  bénéﬁciaires  de  l’Assurance  Mal-
die  (RNIAM;  national  interscheme  directory  of  national
ealth  insurance  beneﬁciaries)  on  1st  January  2011.  The
ost  analysis  was  based  on  the  amount  of  annual  reimburse-
ent  for  each  treatment  according  to  the  refunded  amount
f  each  drug  studied.  Spearman’s  test  was  used  to  identify
egional  correlations  between  standardized  treatment  fre-
uencies  and  standardized  regional  hospitalization  rates  for
troke,  ischaemic  heart  disease  and  heart  failure  in  2008  for
he  overall  population.  Treatment  frequencies  were  stud-
ed  according  to  a  geographic  deprivation  score  expressed  in
uintiles,  established  on  a  scale  based  on  the  place  of  res-
dence  according  to  four  factors:  mean  household  income;
ercentage  of  high  school  graduates  among  the  inhabitants
ged  greater  or  equal  to  15  years;  percentage  of  manual
orkers  in  the  working  population;  and  unemployment  rate
17]. Treatment  frequencies  were  also  studied  according  to
he  degree  of  urbanicity  of  the  French  county  deﬁned  by
ounties  in  which  no  residence  is  separated  from  the  next
y  more  than  200  m.  For  these  two  analyses,  people  living
n  French  Overseas  departments  were  excluded  due  to  a
ack  of  place  of  residence  codiﬁcation.  Statistical  analyses
ere  performed  with  SAS  Enterprise  Guide  4.1  software  (SAS
nstitute,  Inc.,  Cary,  NC,  USA).
Frequency  of  treatment  of  cardiovascular  risk  factors  in  France  277
Table  1  Treatment  frequencies  for  cardiovascular  risk  factorsa and  female/male  ratio  of  frequencies  among  general
scheme  beneﬁciaries  in  2010,  according  to  sex  and  age.
Age  (years)  nb Hypertension  Hyperlipidaemia
Men  (%)
(n  =  4.1)b
Women  (%)




(n  =  9.4)b
Men  (%)
(n  =  3.2)b
Women  (%)




(n  =  6.4)b
0—4  3.7  0.0  0.0  0.0  0.0  0.0  0.0
5—9 3.7 0.0  0.0  0.0  0.0  0.0  0.0
10—14 3.6 0.1 0.1  1.0  0.1  0.0  0.0  0.0
15—19 3.5 0.2 0.2 1.0 0.2 0.0  0.1  0.1
20—24 3.5 0.4 0.6 1.5 0.5 0.1 0.2 2.0 0.1
25—29  3.8  0.7  1.0  1.4  0.9  0.3  0.3  1.0  0.3
30—34  3.9  1.4  1.7  1.2  1.5  0.7  0.4  0.6  0.6
35—39  4.2  2.8  3.3  1.2  3.0  1.9  1.0  0.5  1.4
40—44  4.1  5.7  6.4  1.1  6.0  4.7  2.2  0.5  3.4
45—49  4.1  10.9  11.4  1.0  11.2  9.3  4.6  0.5  6.9
50—54  3.8  19.5  18.9  1.0  19.2  16.8  9.5  0.6  12.9
55—59  3.6  30.5  27.4  0.9  28.8  25.9  17.4  0.7  21.3
60—64  3.5  41.3  36.3  0.9  38.7  34.4  26.5  0.8  30.2
65—69  2.3  50.0  46.2  0.9  48.0  40.8  34.7  0.9  37.5
70—74  2.0  57.9  55.9  1.0  56.8  45.2  41.3  0.9  43.1
75—79  1.8  66.0  65.3  1.0  65.6  48.3  45.5  0.9  46.6
80—84  1.4  71.9  71.9  1.0  71.9  47.4  43.1  0.9  44.6
85—89  0.8  74.8  75.1  1.0  75.0  39.3  33.6  0.9  35.3
≥  90 0.4  70.8  72.4  1.0  72.1  23.6  18.2  0.8  19.4
≥  20  43.3  20.5  22.7  1.1  21.7  15.8  13.8  0.9  14.8
≥  40 27.9  31.9  33.7  1.1  32.9  24.8  20.8  0.8  22.6
≥  60 12.2 54.5  54.6  1.0  54.6  40.8  35.4  0.9  37.7
18—74 38.9  16.3  16.2  1.0  16.3  13.4  10.3  0.8  11.8
Total  57.9  15.0  17.4  1.2  16.3  11.6  10.6  0.9  11.1
Age  (years)  Diabetes
Men  (%)
(n  =  1.3)b
Women  (%)




(n  =  2.5)b
0—4  0.0  0.0  0.0
5—9  0.1  0.1  1.0  0.1
10—14  0.2  0.2  1.0  0.2
15—19  0.2  0.2  1.0  0.2
20—24  0.3  0.3  1.0  0.3
25—29  0.4  0.4  1.0  0.4
30—34  0.5  0.6  1.2  0.5
35—39  0.8  0.8  1.0  0.8
40—44  1.6  1.4  0.9  1.5
45—49  3.1  2.4  0.8  2.7
50—54  5.8  4.2  0.7  4.9
55—59  9.7  6.5  0.7  8.0
60—64 13.7  8.6  0.6  11.0
65—69  17.1  11.2  0.7  14.0
70—74 18.6  13.0  0.7  15.5
75—79  20.0  14.6  0.7  16.8
80—84  19.1  14.1  0.7  15.9
85—89  15.8  11.6  0.7  12.8
≥  90  11.0  8.2  0.7  8.9
≥  20  6.3  4.9  0.8  5.6
≥  40  9.7  7.2  0.7  8.4
≥  60  16.7  11.6  0.7  13.7
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Table  1  (Continued  )
Age  (years)  Diabetes
Men  (%)
(n  =  1.3)b
Women  (%)




(n  =  2.5)b
18—74  5.3  3.8  0.7  4.5
Total  4.6  3.8  0.8  4.2
M: men; W:  women.




















































































reatment  frequencies  for  all  general  scheme  beneﬁciaries
ncluded  in  2010  were  16%  (men,  15%;  women,  17%)  for
ntihypertensive  drugs,  11%  (men,  12%;  women,  11%)  for
ipid-lowering  agents  and  4%  (men,  5%;  women,  4%)  for
ntidiabetic  drugs  (Table  1).  Treatment  frequencies  were
3%,  23%  and  8%,  respectively,  for  patients  aged  greater  or
qual  to  40  years  and  55%,  38%  and  14%,  respectively,  for
hose  aged  greater  or  equal  to  60  years.  Peak  frequencies
ere  observed  in  those  aged  75—79  years  for  lipid-lowering
gent  treatments  (47%)  and  antidiabetics  (17%)  and  in  the
roup  aged  85—89  years  for  antihypertensives  (75%),  in  both
en  and  women.
Regardless  of  the  age  groups,  women  received  antidia-
etic  treatments  and  lipid-lowering  agents  less  often  than
en  (4%  vs.  5%  and  11%  vs.  12%,  respectively),  these  dif-
erences  being  more  marked  over  the  age  of  40  years.  In
ontrast,  women  overall  received  antihypertensive  treat-
ents  more  often  than  men  (17%  vs.  15%),  but  this
ifference  was  only  observed  between  the  ages  of  20  and
4  years.
The  frequency  of  treatment  for  at  least  one  of  the  three
isk  factors  considered  was  41%  in  subjects  aged  greater  or
qual  to  40  years  and  66%  for  those  aged  greater  or  equal  to
0  years  (Table  2).  The  peak  frequency  was  observed  in  those
ged  85—89  years  (81%).  Treatment  frequencies  for  combi-
ations  of  the  various  risk  factors  in  individuals  aged  greater
r  equal  to  40  years  ranged  between  4%  for  triple  combina-
ions  and  15%  for  double  combinations,  most  frequently  an
ntihypertensive  and  a  lipid-lowering  agent.  Treatment  fre-
uencies  with  the  various  combinations  were  higher  in  men
han  in  women  for  almost  all  age  groups.
At  the  regional  level  (Fig.  1),  the  frequency  of  antihy-
ertensive  treatment  standardized  for  age  and  sex  ranged
rom  14%  to  19%.  Regional  differences  were  observed,  with
igher  treatment  frequencies  in  the  North  and  North-East
egions  and  in  the  French  West  Indies,  followed  by  the  Cen-
re  (apart  from  Île-de-France)  and  Reunion  regions.  Lower
reatment  frequencies  were  observed  in  Île-de-France,  Brit-
any  and  in  the  South  and  South-East  regions.  Antidiabetic
reatment  frequencies  ranged  from  3%  to  8%,  and  a  marked
eographical  gradient  was  also  observed,  with  high  treat-
ent  frequencies  in  Overseas  regions,  followed  by  the
orth  and  North-East  regions,  and  lower  frequencies  in
he  Western  regions  of  France.  Regional  differences  were




trequencies  ranging  between  7%  and  13%,  but  with  no
learly  deﬁned  geographical  gradient.  The  highest  treat-
ent  frequencies  were  observed  in  the  North,  North-East,
orth-West,  Centre-West  and  Corsica  regions,  with  lower
requencies  in  Overseas  regions.  Combination  treatments
or  all  three  risk  factors  accentuated  these  conﬁgurations,
ith  high  frequencies  in  the  North,  North-East  and  Overseas
egions.
In  the  population  of  subjects  aged  greater  or  equal  to
0  years  without  CVD,  18%  received  an  antihypertensive,
2%  received  a  lipid-lowering  agent  and  5%  received  an
ntidiabetic  agent  (Table  3);  7%  received  a combination  of
n  antihypertensive  and  a  lipid-lowering  agent  and  2.1%
eceived  a  triple  combination.  Among  subjects  aged  greater
r  equal  to  40  years  without  CVD,  28%  received  an  antihy-
ertensive,  19%  received  a lipid-lowering  agent  and  7.3%
eceived  an  antidiabetic.  Eighty  percent  of  patients  with
VD  received  an  antihypertensive,  71%  received  a  lipid-
owering  agent  and  21%  received  an  antidiabetic.  Among
atients  aged  greater  or  equal  to  60  years,  these  proportions
ere  83%,  70%  and  22%,  respectively.
Fig.  2  and  Table  3  show  the  proportion  of  patients  treated
or  a  given  risk  factor,  according  to  the  presence  or  absence
f  CVD.  In  the  overall  population  aged  greater  or  equal  to
0  years,  25%  were  treated  for  at  least  one  risk  factor:  22%
ad  no  CVD  and  3.4%  had  documentation  of  CVD.  Among
atients  without  CVD  receiving  an  antihypertensive  treat-
ent,  53%  were  not  treated  for  the  other  two  risk  factors,  7%
lso  received  an  antidiabetic,  29%  received  a  lipid-lowering
gent  and  11%  received  treatments  for  all  three  risk  factors.
hese  treatment  frequencies  among  patients  with  at  least
ne  CVD  were  17%,  4%,  59%  and  20%,  respectively.
The  frequency  of  each  treatment  increased  with  the
evel  of  deprivation,  especially  for  diabetes  (Table  4).
his  trend  was  more  marked  in  women  for  each  of  the
hree  risk  factors  studied,  but  women  were  generally
lder  than  men  for  each  quintile.  Antihypertensive  and
ipid-lowering  treatment  frequencies  according  to  eight
eciles  of  urbanization  decreased  for  urban  units  with
ore  than  50,000  inhabitants,  while  the  frequency  of
ntidiabetic  treatments  was  relatively  stable  (data  not
hown).
Age-adjusted  hospitalization  rates  in  France  have
een  previously  published.  In  2008,  these  rates  were
05.1/100,000  for  stroke,  377.4/100,000  for  ischaemic
eart  disease  and  177.5/100,000  for  heart  failure.  Using
hese  estimates,  we  found  a  positive  correlation  between
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Table  2  Treatment  frequencies  for  cardiovascular  risk  factorsa and  combinations  of  risk  factors  among  beneﬁciaries  of
the  general  scheme  in  2010,  according  to  sex  and  age.
Age
(years)
At least  one  factor  Hypertension—hyperlipidaemia  Hypertension—diabetes
Men
(n  =  5.3)b
Women
(n  =  6.5)b
Total
(n  =  11.8)b
Men
(n  =  2.2)b
Women
(n  =  2.1)b
Total
(n  =  4.3)b
Men
(n  =  0.9)b
Women
(n  =  0.9)b
Total
(n  =  1.8)b
0—4  0.1  0.0  0.1  0.0  0.0  0.0  0.0  0.0  0.0
5—9  0.1  0.1  0.1  0.0  0.0  0.0  0.0  0.0  0.0
10—14  0.3  0.3  0.3  0.0  0.0  0.0  0.0  0.0  0.0
15—19  0.5  0.5  0.5  0.0  0.0  0.0  0.0  0.0  0.0
20—24 0.8 1.0  0.9  0.0  0.0  0.0  0.0  0.0  0.0
25—29 1.2 1.6 1.4 0.1 0.0  0.0  0.0  0.0  0.0
30—34 2.3 2.5 2.4 0.2 0.1 0.1 0.1 0.1 0.1
35—39 4.6 4.5 4.5 0.6 0.3 0.5 0.2 0.2 0.2
40—44  9.2  8.5  8.8  1.8  0.8  1.3  0.6  0.5  0.6
45—49  16.8  14.8  15.8  4.3  2.0  3.1  1.6  1.2  1.4
50—54  28.3  24.8  26.4  9.2  4.7  6.8  3.5  2.6  3.0
55—59  41.7  36.5  38.9  16.2  9.4  12.6  6.7  4.5  5.5
60—64  53.8  48.2  50.8  23.7  15.6  19.3  10.3  6.5  8.3
65—69  62.5  59.2  60.8  30.0  22.7  26.1  13.6  9.2  11.2
70—74  69.5  68.7  69.1  35.2  29.5  32.0  15.3  11.1  13.0
75—79  76.2  76.4  76.3  39.7  35.3  37.1  17.0  12.8  14.5
80—84  80.7  80.2  80.4  40.1  35.6  37.2  16.4  12.6  14.0
85—89  81.8  80.5  80.9  33.9  29.0  30.5  13.5  10.4  11.3
≥  90  75.5  75.4  75.4  20.4  16.0  17.0  9.2  7.2  7.7
≥  20  26.4  28.1  27.3  10.9  9.3  10.0  4.6  3.8  4.1
≥  40  40.8  41.3  41.1  17.3  14.0  15.5  7.3  5.7  6.4
≥  60  65.8  65.4  65.6  31.2  25.6  28.0  13.5  9.8  11.3
18—74  22.0  21.1  21.5  8.7  6.1  7.3  3.7  2.7  3.1
Total  19.3  21.5  20.5  8.0  7.1  7.5  3.4  2.9  3.1
Age  (years)  Diabetes-hyperlipidaemia  Three  factors
Men
(n  =  0.8)b
Women
(n  =  0.6)b
Total
(n  = 1.4)b
Men
(n  =  0.7)b
Women
(n  =  0.5)b
Total
(n  =  1.2)b
0—4  0.0  0.0  0.0  0.0  0.0  0.0
5—9  0.0  0.0  0.0  0.0  0.0  0.0
10—14  0.0  0.0  0.0  0.0  0.0  0.0
15—19  0.0  0.0  0.0  0.0  0.0  0.0
20—24  0.0  0.0  0.0  0.0  0.0  0.0
25—29  0.0  0.0  0.0  0.0  0.0  0.0
30—34  0.1  0.1  0.1  0.0  0.0  0.0
35—39  0.2  0.1  0.2  0.1  0.1  0.1
40—44  0.7  0.4  0.5  0.4  0.2  0.3
45—49  1.6  0.9  1.2  1.0  0.6  0.8
50—54  3.5  2.0  2.7  2.4  1.4  1.9
55—59  6.3  3.6  4.8  4.8  2.8  3.7
60—64  9.2  5.3  7.2  7.6  4.3  5.8
65—69 11.8  7.4  9.5  10.0  6.3  8.0
70—74 12.8 8.7  10.6  11.2  7.7  9.3
75—79 13.6  9.7  11.3  12.2  8.8  10.2
80—84  12.1  8.5  9.8  10.9  7.9  9.0
85—89  8.3  5.7  6.5  7.5  5.3  6.0
≥  90  3.9  2.5  2.9  3.5  2.4  2.6
≥  20  4.0  2.8  3.3  3.2  2.4  2.8
≥  40  6.3  4.2  5.2  5.2  3.6  4.3
≥  60  11.1  7.2  8.9  9.6  6.3  7.7
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Table  2  (Continued  )
Age  (years)  Diabetes-hyperlipidaemia  Three  factors
Men
(n  =  0.8)b
Women
(n  =  0.6)b
Total
(n  =  1.4)b
Men
(n  =  0.7)b
Women
(n  =  0.5)b
Total
(n  =  1.2)b
18—74  3.3  2.1  2.7  2.6  1.7  2.2
Total  2.9  2.1  2.5  2.4  1.8  2.1
Data are percentages.




















































































tegional  stroke  hospitalization  rate  and  the  frequency  of
ntidiabetic  treatment  (r  =  0.62,  P  =  0.007),  the  treatment
requency  of  all  three  risk  factors  (r  =  0.57,  P  = 0.002)  and  the
requency  of  antihypertensive  treatment  (r  =  0.40,  P  =  0.04),
ut  not  of  lipid-lowering  agents.  On  the  contrary,  only
he  regional  frequency  of  lipid-lowering  agents  was  corre-
ated  with  the  ischaemic  heart  disease  hospitalization  rate
r  =  0.45,  P  =  0.02).  Only  moderate  and  borderline  signiﬁcant
orrelations  were  observed  between  the  heart  failure  hos-
italization  rate  and  treatment  frequencies  (r  between  0.40
nd  0.45,  P  <  0.05).
Among  patients  without  CVD,  the  annual  costs  of  reim-
ursement  of  treatments  were  D  749  million  (D  360  per
erson  treated)  for  antidiabetics,  D  761  million  (D  144  per
erson  treated)  for  lipid-lowering  agents  and  D  1,417  mil-
ion  (D  173  per  person  treated)  for  antihypertensives,  i.e.  a
lobal  cost  of  almost  D  3  billion  a  year  for  the  French  national
ealth  insurance  general  scheme.
iscussion
his  study,  based  on  a  population  of  almost  58  million
ational  health  insurance  general  scheme  beneﬁciaries  (90%
f  the  population)  living  in  France,  a  country  with  low
ardiovascular  mortality  and  universal  health  insurance
overage,  reports  a  high  frequency  of  treatment  for  cardio-
ascular  risk  factors  (antihypertensives,  16%;  lipid-lowering
gents,  11%;  antidiabetics,  4%;  and  at  least  one  treatment,
0%)  in  2010,  particularly  in  patients  aged  greater  or  equal
o  40  years  (antihypertensives,  33%;  lipid-lowering  agents,
3%;  antidiabetics,  8%;  at  least  one  treatment,  41%).  It  also
eports  marked  variations  of  treatment  frequencies  accord-
ng  to  age  groups  and  between  regions,  as  well  as  several
ex-related  differences.
ardiovascular risk factors
omparisons  of  the  prevalence  rates  of  risk  factors  between
urveys  are  sometimes  limited  by  differences  in  the  methods
f  measurement,  criteria,  age  structures  and  heterogeneous
opulations.  In  France,  the  Étude  Nationale  Nutrition  Santé
ENNS;  national  health  nutrition  study)  was  based  on  a
ample  of  2413  participants  aged  between  18  and  74  years
n  2006—2007  [18].  The  prevalence  of  known  or  unknown
ypertension  (systolic  blood  pressure  ≥  140  mmHg,  diastolic




pas  31%  (34%  in  men;  28%  in  women),  while  the  prevalence
f  treated  hypertension  was  only  15%,  similar  to  the  16%  rate
eported  in  the  present  study.  Only  one  half  of  the  hyperten-
ive  patients  treated  in  ENNS  presented  satisfactory  blood
ressure  control  according  to  current  guidelines  [19].  In
006—2007,  a  regional  French  survey  (the  MONA  LISA  study)
onducted  in  a  sample  of  4825  participants  aged  between
5  and  74  years  with  an  identical  deﬁnition  of  hypertension
o  that  of  the  ENNS  study,  reported  an  adjusted  prevalence
f  hypertension  of  47%  in  men  and  35%  in  women  and,  as
n  the  present  study,  a  higher  prevalence  in  the  North  and
ast  of  France  (Lille  and  Strasbourg)  than  in  the  South  of
rance  (Toulouse)  [20].  Almost  80%  of  patients  with  known
ypertension  were  treated.  The  ENNS  study  also  noted  that,
ompared  with  1996,  the  prevalence  of  hypertension  had
ecreased  by  7%  in  men  and  18%  in  women  and  blood  pres-
ure  control  had  improved.  International  comparisons  based
n  the  same  deﬁnitions  show  that  the  prevalence  of  hyper-
ension  in  the  United  States  in  2007—2008  in  patients  aged
reater  or  equal  to  18  years  was  29%  and  the  prevalence  of
reated  hypertension  was  19%,  with  an  improvement  of  the
roportion  of  patients  treated  with  adequate  control  [14].  In
ngland  in  2006  in  patients  aged  greater  or  equal  to  16  years
he  prevalence  of  hypertension  was  30%  and  the  prevalence
f  treated  hypertension  was  about  16%  [15].  These  preva-
ence  rates  of  treated  hypertension  were  therefore  slightly
ower  than  that  observed  in  the  present  study,  i.e.  22%  in
atients  aged  greater  or  equal  to  20  years.  All  these  data
oncerning  hypertension  suggest  that,  despite  an  increas-
ngly  frequent  use  of  antihypertensive  drugs  (in  one  third  of
atients  aged  ≥  40  years),  the  treated  population  represents
nly  one  half  of  all  hypertensive  patients  and,  even  when
ypertension  is  treated,  optimal  blood  pressure  control  is
ot  always  achieved.
The  2006—2007  ENNS  study  reported  a  prevalence
f  hypercholesterolemia  of  30%  (treatment  or  LDL-
holesterolemia  >  1.6  g/L)  in  participants  aged  between  18
nd  74  years  (33%  in  men  and  27%  in  women)  and  speciﬁc
reatment  for  13%  of  patients  (about  a  third  of  dyslipidaemic
atients),  close  to  the  12%  rate  reported  in  the  present
tudy  [18]. The  MONA  LISA  study  reported  a  reduction
f  the  prevalence  of  high  low-density  lipoprotein  choles-
erol  concentrations  in  patients  aged  35—64  years  (42%
n  1996—1997  and  36%  in  2006—2007)  [21].  In  the  USA,
n  1999—2006,  the  prevalence  of  hypercholesterolaemia
cholesterol  >  240  mg/dL  or  treatment)  was  26%,  while  the
revalence  of  undiagnosed  hypercholesterolaemia  was  8%









dFigure 1. Regional treatment frequencies for cardiovascular risk
eﬁciaries in 2010, adjusted for age and sex. *A patient treated for
hypertension—diabetes.
[22].  Even  more  than  with  antihypertensive  treatments,
these  other  data  source  indicate  that  the  proportion  of  the
population  treated  for  dyslipidaemia  represents  only  a  small
share  of  the  real  prevalence  of  dyslipidaemia,  indicating  the
need  for  continuing  improvement  in  the  mean  lipid  concen-
trations  of  the  population.
The  ENNS  study  reported  a  prevalence  of  diabetes  of  4.6%
for  participants  aged  between  18  and  74  years  on  the  basis
of  abnormal  fasting  blood  glucose  and/or  speciﬁc  treat-
ment,  with  20%  of  patients  with  untreated  diabetes  [23].




aors and combinations of risk factors among general scheme ben-
rtension and diabetes was counted in hypertension, diabetes and
2.9—4.8%),  consistent  with  that  estimated  in  our  population
4.5%  in  those  aged  18—74  years),  in  view  of  the  large  conﬁ-
ence  interval  in  ENNS.  In  the  USA,  the  global  age-adjusted
revalence  of  diabetes  for  patients  aged  greater  or  equal
o  20  years  is  much  higher,  with  an  estimated  prevalence
f  9.9%  in  1999—2006,  and  a  prevalence  of  undiagnosed
iabetes  of  2.7%  [24,25].  The  ENNS  study  also  reported
ntihypertensive  treatment  in  76%  of  diabetic  patients  and
tatin  treatment  in  52%  of  these  patients,  similar  to  the
oncomitant  treatment  rates  of  74%  for  antihypertensives
nd  59%  for  lipid-lowering  agents  (including  statins)  among
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Table  3  Treatment  frequencies  for  cardiovascular  risk  factors  in  2010,  according  to  the  primary  or  secondary  type  of
prevention  of  cardiovascular  diseases  and  according  to  age,  among  general  scheme  beneﬁciaries.
Age  (years)  Absence  of  cardiovascular  diseasea






HL—HT  (%)  HL—HT
diabetes  (%)
0—4  40.3  0.01  0.00  0.02  0.0  0.0  0.0  0.0
5—9  37.8  0.03  0.01  0.08  0.0  0.0  0.0  0.0
10—14  36.2  0.06  0.02  0.17  0.0  0.0  0.0  0.0
15—19  37.7  0.18  0.05  0.23  0.0  0.0  0.0  0.0
20—24  39.0  0.41  0.11  0.28  0.01  0.01  0.01  0.0
25—29  36.4  0.86  0.25  0.40  0.04  0.02  0.04  0.01
30—34 35.7  1.5  0.57  0.56  0.08  0.07  0.12  0.03
35—49  38.3  3.0  1.4  0.86  0.2  0.2  0.4  0.1
40—44  38.0  5.9  3.2  1.5  0.5  0.5  1.0  0.3
45—49  37.4  10.6  6.2  2.7  1.3  1.1  2.4  0.7
50—54  35.0  17.8  11.4  4.7  2.7  2.4  5.3  1.6
55—59  33.1  26.4  18.7  7.4  4.8  4.2  9.9  3.1
60—64 31.7  35.2  26.7  9.9  7.2  6.1  15.6  4.8
65—69  20.1  43.3  33.0  12.5  9.6  8.0  21.2  6.6
70—74 16.8  51.3  37.7  13.9  11.2  8.9  26.0  7.6
75—79 14.1 58.5  40.0  14.8  12.4  9.4  29.8  8.2
80—84 10.2  62.5  36.7  13.7  11.7  8.0  28.9  7.1
85—89 6.1 63.2  27.5  10.9  9.3  5.2  22.6  4.6
≥  90 2.8 55.0 13.3 7.1  5.9  2.1  11.3  1.9
≥  20 394.7 18.2 12.0  4.8  3.3  2.7  7.3  2.1
≥  40 245.2 28.4 19.0 7.3  5.3  4.2  11.7  3.4
≥  60 101.7 47.6 32.3 12.1 9.6  7.4  22.0  6.2
20—74 361.5 14.3 10.0  4.0  2.6  2.2  5.6  1.7
Total 546.7 13.1 8.7 3.5  2.4  1.9  5.3  1.5
Age  (years)  Presence  of  cardiovascular  disease
n/1000  HT  (%)  HL  (%)  Diabetes  (%)
0—4  1.3  2.9  0.08  0.23
5—9  0.9  3.0  0.00  0.00
10—14  0.9  3.9  0.33  0.22
15—19  1.2  6.0  2.4  1.02
20—24  1.8  9.3  6.2  0.91
25—29  2.8  16.5  14.5  2.1
30—34  4.9  29.3  29.1  3.9
35—49  11.5  44.5  46.7  5.4
40—44  25.9  58.1  62.0  8.7
45—49 53.0  66.5  70.9  12.2
50—54  95.4  72.8  76.2  16.9
55—59  146.9  77.4  79.5  21.2
60—64  201.3  81.4  81.6  24.4
65—69  179.0  83.7  81.6  26.3
70—74  207.2  85.4  80.4  25.4
75—79  242.3  85.7  76.1  24.1
80—84  234.5  84.0  67.4  20.1
85—89  177.1  80.3  51.9  14.6
≥  90  93.6  72.7  28.6  9.0
≥  20  1677.1  80.2  70.9  20.6
≥  40  1656.1  80.8  71.3  20.8
≥  60  1335.0  82.8  70.3  21.6
20—74  929.6  78.6  78.2  22.1
Total  1681.4  80.1  70.7  20.6
HL: hyperlipidaemia; HT: hypertension.
a Coronary heart disease and myocardial infarction, stroke and peripheral artery disease.
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Figure 2. Proportion of general scheme beneﬁciaries treated for a given risk factor and also receiving treatment for other risk factors in
2010, according to the presence or absence of cardiovascular disease, according to age. *Coronary heart disease and myocardial infarction,




and  North-East  regions  (17%  to  20%)  [27,28]. In  national  sur-the  diabetic  patients  of  our  study  in  2010.  This  emphasizes
the  high  cardiovascular  risk  of  diabetic  patients,  as  already
reported  by  other  authors  [26].
The  other  major  cardiovascular  risk  factors  cannot  be
assessed  from  the  data  available  in  SNIIRAM,  but  the  results
of  speciﬁc  studies  conducted  on  these  risk  factors  contribute
to  those  of  the  present  study.  The  OBEPI  study  conducted
v
1
on  2009  reported  that  32%  of  French  adults  aged  greater  or
qual  to  18  years  were  overweight  and  14%  were  obese  (men,
4%;  women,  15%).  Obesity  was  more  frequent  in  the  Northeys,  the  self-reported  prevalence  of  smoking  in  those  aged
2—75  years  was  30%  in  2005  versus  33%  in  2000,  with  rates
f  33%  for  men  and  26%  for  women  [29].  The  prevalence
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Table  4  Treatment  frequencies  for  each  risk  factor  in  2010,  among  general  scheme  beneﬁciaries  aged  greater  or  equal  to
20  years  without  cardiovascular  disease  (CVD),  according  to  a geographic  deprivation  score  ranging  from  1  (less  deprived)
to  5  (more  deprived).
Quintiles  Deprivation  index  5th  quintile/1st
quintile  ratio1  2  3  4  5
Men  (n)a 7.6 4.8 3.6 3.9 4.2
Women  (n)a 8.8  5.6  4.2  4.6  4.8
Men:  mean  age  (years)  36.4  36.6  37.1  37.0  36.1
Females:  mean  age  (years)  39.2  39.7  40.4  40.3  39.0
Treatments  (%)
Antihypertensive,  men  13.9  14.9  16.0  16.3  16.1  1.16
Antihypertensive,  women  14.5  16.3  17.8  18.5  18.8  1.30
Lipid-lowering  agent,  men 11.0  11.6  12.5  12.5  12.3  1.11
Lipid-lowering  agent,  women  8.9  10.0  10.9  11.2  11.4  1.27
Antidiabetic,  men  4.0  4.6  4.8  5.2  5.4  1.35
Antidiabetic,  women  2.8  3.4  3.8  4.1  4.7  1.69





































































f  smoking  among  men  has  almost  halved  over  the  last  30
ears,  while  the  trend  towards  a  decrease  in  smoking  among
omen  started  later,  after  1991.
isk factors and prevention
hese  data  suggest  the  possibility  of  preventative  actions
irected  towards  speciﬁc  populations,  in  particular  some
epartments,  patients  with  lower  socioeconomic  status,  and
peciﬁc  age  and  sex  groups.  The  North-East  and  Overseas
epartments  present  a  high  cardiovascular  risk,  particularly
or  antihypertensives  and  antidiabetics.  While  geographical
ariations  in  screening,  diagnosis  and  treatment  practices
re  possible,  these  variations  are  similar  to  those  of  regional
tandardized  hospitalization  rates  for  myocardial  infarc-
ion  and  coronary  heart  disease,  stroke  and,  especially,
eart  failure  [30].  Hospitalization  rates  for  CVD  are  known
o  be  higher  among  lower  socioeconomic  categories  [31],
ut  the  association  between  cardiovascular  risk  factors
nd  diseases  with  socioeconomic  status  has  rarely  been
eported  in  France.  While  the  level  of  adequacy  of  treat-
ent  and  control  of  risk  factors  could  not  be  assessed  in
ur  study,  the  higher  risk  factor  treatment  frequencies  that
e  observed  in  the  most  deprived  populations  may  jus-
ify  more  aggressive  screening  and  management  of  these
actors  in  these  populations,  assuming  that  they  were  not
ore  adequately  treated  than  the  general  population.  We
lso  observed  the  expected  sex  differences,  with  overall
igher  treatment  frequencies  in  the  elderly  and  in  men.
owever,  we  reported  a  higher  treatment  use  of  antihy-
ertensive  agents  in  women  aged  20—44  years,  as  observed
y  other  French  (ENNS),  British  and  North  American  stud-
es  [14,15].  This  could  be  explained  by  early  detection  and
reatment  facilitated  by  more  frequent  medical  consulta-
ions  (contraception,  pregnancy,  etc.).  However,  despite  a
ower  prevalence  of  hypertension  and  a  slightly  higher  treat-
ent  frequency  in  young  women  than  in  men,  the  adjusted




in  women  aged  less  than  65  years  were  reported  to  have
ncreased  between  2002  and  2008  in  France.  This  could
e  partially  explained  by  cardiovascular  risk  factors  other
han  those  investigated  in  this  study,  particularly  smoking,
besity  and,  possibly,  oral  contraception.  Moreover,  women
ged  les  than  60  years  with  complementary  universal  medi-
al  coverage,  attributed  in  France  to  people  with  an  income
elow  the  poverty  threshold,  have  about  a twofold  higher
ospitalization  rate  for  hypertension,  stroke  and  myocardial
nfarction  compared  with  women  without  complementary
niversal  medical  coverage  [31].  Speciﬁc  prevention  actions
ould  therefore  also  be  directed  towards  relatively  young
omen  from  low  socioeconomic  categories.
atients with several risk factors may be
nother major target for prevention
 recent  meta-analysis  demonstrated  the  high-risk  of  experi-
ncing  myocardial  infarction  or  stroke  during  lifetime  in  the
resence  of  several  risk  factors  [32]. For  men  aged  45  years,
he  presence  of  at  least  two  risk  factors  among  hyperten-
ion,  hyperlipidaemia,  diabetes  and  smoking  is  associated
ith  an  excess  risk  of  49%.  Also,  treatments  of  the  various
ardiovascular  risk  factors  may  not  all  have  the  same  impact
n  cardiovascular  morbidity  and  mortality.  For  example,  an
merican  study  attributed  a  24%  reduction  in  mortality  for
eduction  of  total  cholesterol,  a  20%  reduction  for  reduction
f  systolic  blood  pressure  and  a  12%  reduction  for  reduction
f  smoking  prevalence  [33].
This  study  also  illustrates  the  predominant  role  of  pri-
ary  prevention  compared  with  secondary  prevention  of
VD.  Over  the  age  of  20  years,  22%  of  the  population  is
reated  for  at  least  one  risk  factor  in  the  absence  of  CVD,
ersus  only  3%  for  at  least  one  risk  factor  in  the  pres-
nce  of  CVD.  While  a  population-based  approach  therefore
ppears  to  be  necessary,  its  impact  may  look  small  in  view
f  the  low  proportion  of  events  concerned.  Various  stud-


























RFrequency  of  treatment  of  cardiovascular  risk  factors  in  Fra
prevention  measures  on  the  reduction  of  coronary  mortality
[33—36].  According  to  one  of  these  studies,  primary  preven-
tion  measures  appeared  to  be  responsible  for  about  40%  of
the  reduction  of  mortality,  while  the  rest  was  due  to  ini-
tial  management  and  secondary  prevention  [33].  In  another
English  study,  primary  prevention  had  a  fourfold  higher
impact  on  reduction  of  mortality  compared  with  secon-
dary  prevention  [35].
Eventually,  while  the  efﬁcacy  of  the  two  strategies  is
improved  by  statins  and  the  arrival  of  less  expensive  gene-
rics,  the  positive  effect  of  drug  management  of  major
cardiovascular  risk  factors  on  cardiovascular  mortality  is
likely  to  be  decreased  by  the  obesity  and  diabetes  epidemic
and  probably  by  the  high  rate  of  persistent  smoking  [34].
Study limitations
This  study  was  based  on  a  large  population  covered  by  the
French  national  health  insurance  general  scheme  (90%  of
the  French  population).  However,  some  population  groups
insured  by  other  schemes  due  to  their  occupation  or  their
sector  of  activity  may  differ  in  terms  of  their  sociodemo-
graphic  characteristics  and  habitat,  but  also  according  to  the
frequency  of  risk  factors  and  their  management.  However,
the  impact  of  this  bias  on  our  results  is  probably  low.  The
prevalence  of  CVD  may  also  have  been  underestimated,  as
the  data  analyzed  in  this  study  were  derived  from  adminis-
trative  databases  with  their  classical  limitations  concerning
their  primary  objective,  i.e.  data  collection  and  coding.
It  is  therefore  possible  that  some  patients  may  have  been
incorrectly  classiﬁed  in  the  various  groups  of  CVD.  Finally,
the  frequency  of  antihypertensive  treatment  may  overes-
timate  the  prevalence  of  treated  hypertension,  as  some
medicinal  products  are  also  indicated  in  the  treatment  of
angina,  cardiac  disorders  and  heart  failure,  which  are  more
frequent  diseases  in  the  elderly.  Finally,  treatment  use,  as
commented  in  the  discussion  section,  partially  reﬂects  the
prevalence  of  risk  factors  and  does  not  provide  information
on  the  control  of  risk  factors.
Conclusion
In  a  historical  context  of  reduction  of  global  morbidity
and  mortality  rates  related  to  CVD,  this  study  highlights
the  predominant  role  of  treatments  for  primary  preven-
tion  of  CVD  and  emphasizes  the  considerable  proportion
of  intermediate-  and  high-risk  patients  already  treated.
Despite  this  large  proportion,  the  results  of  other  stud-
ies  show  that  progress  still  needs  to  be  made  to  delay  or
limit  the  frequency  of  CVD  and  to  more  effectively  detect,
treat  and  control  cardiovascular  risk  factors.  In  this  set-
ting,  the  present  study  identiﬁes  populations  with  high
levels  of  treatment,  but  in  age  and  sex  groups  and  regions
that  also  have  high  levels  of  cardiovascular  morbidity  or
other  cardiovascular  risk  factors.  It  is  necessary  to  ensure
that  treatment  and  control  are  adequate  for  the  level  of
risk  in  these  groups:  the  departments  of  the  North-East
region  of  France,  Overseas  departments  and  metropolitan
zones;  and  the  elderly,  men,  but  also  young  women,  in
whom  hospitalization  rates  for  CVD  appear  to  be  increasing.
The  Caisse  Nationale  d’Assurance  Maladie  des  Travailleurs285
alariés  (French  salaried  workers’  national  health  insurance
und)  has  set  up  several  programmes  concerning  the  man-
gement  of  these  risk  factors.  One  of  the  main  programmes
s  SOPHIA,  a  support  programme  for  diabetic  patients  that  is
urrently  being  extended  nationwide.  Since  2010,  the  car-
iovascular  risk  prevention  programme  is  designed  to  more
ccurately  evaluate  the  global  cardiovascular  risk,  optimi-
ing  identiﬁcation  of  patients  at  high  cardiovascular  risk  by
ncreasing  the  awareness  of  a  large  population  to  the  value
f  non-pharmaceutical  measures  (smoking  cessation,  diet,
hysical  activity).  An  active  health  programme  is  also  being
eveloped  for  2013  with  a  diet  component  for  the  so-called
ow-risk  population  and  a cardiac  health  component  for  the
o-called  high-risk  population.  More  action  to  prevent  the
econd  leading  cause  of  death  in  France  is  still  required.
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